Combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
Pharmaceutical compositions comprising an anticholinergic and at least one leukotriene inhibitor for treatment of respiratory diseases, including allergic rhinitis, bronchial asthma, COPD and common cold, and methods of treatment.
1. Combination of R,R-glycopyrrolate or a physiologically acceptable salt thereof and montelukast or a physiologically acceptable salt thereof for the treatment of respiratory diseases selected from the group consisting of allergic rhinitis, bronchial asthma, and COPD to provide a daily dose of montelukast from 1 to 100 mg, and a daily dose of R,R-glycopyrrolate from 1 to 500 μg.
2. Combination according to claim 1 where the daily dose of montelukast is from 5 to 20 mg.
3. The combination according to claim 1 wherein the daily dose of R,R-glycopyrrolate is from 5 to 100 μg.
4. A pharmaceutical for the treatment of respiratory diseases selected from the group consisting of allergic rhinitis, bronchial asthma, and COPD, comprising R,R-glycopyrrolate or a physiologically acceptable salt thereof and montelukast or a physiologically acceptable salt thereof to provide a daily dose of montelukast from 1 to 100 mg, and a daily dose of R,R-glycopyrrolate is from 1 to 500 μg.
5. The pharmaceutical according to claim 4 , where the active substances are available readily mixed in a fixed combination, if appropriate together with excipients, adjuncts, and additives in a pharmaceutical form suitable for inhalative application.
6. The pharmaceutical according to claim 4 , wherein the active substances are available in separate packing units whereby both substances can be taken from the separate packing units in such a way that they are available for simultaneous inhalative application.
7. The pharmaceutical according to claim 6 , wherein the active substances can be applied independently from each other.
8. The pharmaceutical according to claim 5 , characterized in that it is an inhalable aerosol with or without propellant.
9. The pharmaceutical according to claim 5 , characterized in that it is an inhalable dry powder.
10. The pharmaceutical according to claim 5 , characterized in that it is an inhalable suspension or solution.
11. The pharmaceutical according to claim 5 presented in an inhaler.
12. A method of making a pharmaceutical according to claim 4 for the treatment of respiratory diseases selected from the group consisting of allergic rhinitis, bronchial asthma, and COPD in a mammal, said method comprising combining R,R-glycopyrrolate or a physiologically acceptable salt thereof and montelukast or a physiologically acceptable salt thereof.
13. The method according to claim 12 wherein the mammal is selected from the group consisting of cats, dogs, or horses.
14. The method according to claim 12 wherein the diseases are selected from the group consisting of asthma and chronic obstructive pulmonary disease (COPD).
15. A method of treating inflammation associated with a respiratory disease selected from the group consisting of allergic rhinitis, bronchial asthma, and COPD in a mammal in need thereof comprising administering a daily dose of R,R-glycopyrrolate or a physiologically acceptable salt thereof in an amount of from 1 to 500 μg and a daily dose of montelukast or a physiologically acceptable salt thereof in an amount of from 1 to 100 mg to said mammal in dosages thereby reducing inflammation associated with the respiratory disease.
16. The method according to claim 15 characterized in that the mammal is selected from the group consisting of cats, dogs, or horses.
17. The method according to claim 15 where the diseases are selected from the group consisting of asthma and chronic obstructive pulmonary disease (COPD).